Chronic blockade of gut beta-CGRP by mABs could theoretically contribute to modifying the physiological homeostasis of the intestinal mucosa in patients with inflammatory bowel diseases and, considering that there is a comorbidity between migraines and IBD [22], the status of IBD in patients with mAbs should be closely monitored. The gene discussed is CALCB; the disease is inflammatory bowel disease.